This included using NFL to discriminate between patients with and without vasculitic neuropathy,53 symptomatic vs asymptomatic hereditary transthyretin-mediated amyloidosis with polyneuropathy,49 and between patients with Charcot-Marie-Tooth disease and healthy controls.35,38,39 Future research considering the optimal type of blood analysis and immunological assay is needed to develop generally accepted clinical diagnostic cutoffs for patients with different types of peripheral neuropathy. The gene discussed is NEFL; the disease is peripheral neuropathy.